Ulka Vaishampayan, MD, FASCO

 Ulka N. Vaishampayan
Research Professor of Cancer Research
Clinical Professor of Internal Medicine, Medical School
Office:
Michigan Medicine
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Email:
[email protected]
Phone:
Available to mentor
Ulka Vaishampayan, MD, FASCO
Ulka N. Vaishampayan
Clinical Professor
  • About
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    Ulka Vaishampayan, MD, is a Professor of Internal Medicine and the Director of the Phase 1 Program and co-leader of the Translational and Clinical Research Program at the University of Michigan Rogel Cancer Center, Ann Arbor MI. She is also the Chair of the SWOG Advanced Renal Committee, a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. She is the PI of the Kidney Cancer Research Consortium grant awarded by the Dept of Defense. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development and biomarkers. She has authored or coauthored numerous publications focusing on novel therapeutics for patients with genitourinary malignancies.

    Center Memberships
    • Center Member
      Rogel Cancer Center

    Research Overview

    Kidney cancer
    Prostate cancer
    Novel drug development
    Biomarker development
    Cancer Screening

    Recent Publications

     See All Publications
    • Journal Article
      10 Outcomes of Patients with Renal Cell Carcinoma Achieving Pathologic Complete or Major Response After Consolidative Nephrectomy Following Immune Checkpoint Inhibitor Therapy
      do Amaral PS, Mehra R, Gordetsky JB, Zhang T, Kapur P, Brugarolas J, Issa W, Abdullah S, Vaishampayan UN, Wood L, McKay RR, Panian JA, Zhang H, Bigarella M, Freeman RS, Gokden N, Ornstein MC, Przybycin C, Hakimi AA, Lopez AS, Shyr Y, Hsu C-Y, Rini B. The Oncologist, 2026 Sep 3; 31 (Supplement_3): oyag312.011 DOI:10.1093/oncolo/oyag312.011
      PMID: PMC13535346
    • Journal Article
      16 ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy
      Hammers H, Calvo E, Carneiro BA, Harrison MR, Jonasch E, Braun D, Oh D-Y, Seghal K, Vaishampayan U, Yamamoto N, Emens LA, Tang J, Nguyen A, Prem N, Trujillo D, Hartman C, Paddock M, Powell J, McDermott D. The Oncologist, 2026 Sep 3; 31 (Supplement_3): oyag312.017 DOI:10.1093/oncolo/oyag312.017
      PMID: PMC13535347
    • Journal Article
      A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer
      Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karabürk H, Bhattacharyya R, Yin Y, Zhao Y, Liu W, Cao X, Xue H, Li C, Wang Z, Miner SJ, Reichert ZR, Mehra R, Vaishampayan U, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Chinnaiyan AM, Qiao Y. Cancer Cell, 2026 Sep 14; 44 (9): 1761 - 1778.e12. DOI:10.1016/j.ccell.2026.07.003
      PMID: 42546705
    • Additional Scholarship
      Figure 2 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.28367834
    • Additional Scholarship
      Figure 4 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.28367828
    • Additional Scholarship
      Figure 5 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.28367825
    • Additional Scholarship
      Supplementary Figure S1 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.32700772
    • Additional Scholarship
      Supplementary Figure S10 from The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
      Bao Y, Cruz G, Zhang Y, Qiao Y, Mannan R, Hu J, Yang F, Gondal M, Shahine M, Kang S, Mahapatra S, Chu A, Choi JE, Yu J, Lin H, Miner SJ, Robinson DR, Wu Y-M, Zheng Y, Cao X, Su F, Wang R, Hosseini N, Cieslik M, Kryczek I, Vaishampayan U, Zou W, Chinnaiyan AM. 2026 Jun 17; DOI:10.1158/2159-8290.32700769